We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Natural Antibodies Can Prevent Adverse Immune Reactions

By LabMedica International staff writers
Posted on 11 Mar 2019
Natural antibodies, in particular IgG, have been shown to be a critical factor that determines the efficiency of complement activation in different subjects and by different nanomaterials.

Deposition of complement factors (opsonization) on nanoparticles may promote clearance from the blood by macrophages and trigger pro-inflammatory responses, but the mechanisms regulating the efficiency of complement activation are poorly understood.

Opsonization is the molecular mechanism whereby molecules, microbes, or apoptotic cells are chemically modified to have stronger interactions with cell surface receptors on phagocytes and natural killer (NK cells). More...
With the antigen coated in opsonins, binding to immune cells is greatly enhanced. Opsonization also mediates phagocytosis via signal cascades from cell surface receptors. Opsonins aid the immune system in a number of ways: in a healthy individual, they mark dead and dying self-cells for clearance by macrophages and neutrophils, activate complement proteins, and target cells for destruction through the action of NK cells.

Investigators at the University of Colorado (Aurora, CO, USA) previously found that opsonization of superparamagnetic iron oxide (SPIO) nanoworms with the third complement protein (C3) was dependent on the biomolecule corona of the nanoparticles. C3 is a molecule that plays a central role in the activation of the complement system, and its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection.

In a paper published in the January 14, 2019, online edition of the journal Nature Nanotechnology, the investigators reported that binding of only a few immunoglobulin molecules, and specifically IgG, determined the efficiency of C3 deposition on nanomaterials introduced into the plasma and sera of healthy donors and in plasma of cancer patients, regardless of the complement activation pathway. Moreover, the presence of the biomolecule corona enhanced IgG binding to all tested nanomaterials.

“In all of the nanoparticles that we tested, complement activation was dependent on the binding of certain of these natural antibodies to nanoparticles,” said senior author Dr. Dmitri Simberg, associate professor of pharmaceutical sciences at the University of Colorado. “Interestingly, the antibodies bind to the proteins in the corona, rather than to the pristine nanoparticle surface itself. If a person has a high level of antibodies that can recognize a particular type of nanoparticle, this person will have high complement activation. The study gave us an exciting new angle on how the system recognizes nanomaterials. This knowledge step is important for designing a better coating so the particles can be more biocompatible and safer. I am a really big fan and proponent of mechanistic studies in the nanodrug delivery field that can guide us to better designs.”

Related Links:
University of Colorado


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.